ImmunoGen, Inc. News Releases http://investor.immunogen.com/ ImmunoGen, Inc. News Releases en ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer http://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-mature-data-forward-ii-expansion-cohort Results to be Presented at 2019 ASCO Annual Meeting Combination Demonstrates Significant Anti-Tumor Activity and Favorable Safety and Tolerability in Platinum-Resistant Disease Findings Support Ongoing Studies of Doublet Combination in Platinum-Agnostic Disease and Triplet in Platinum-Sensitive Wed, 15 May 2019 17:01:00 -0400 ImmunoGen, Inc. News Releases 18801 ImmunoGen Provides Regulatory Update on Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer http://investor.immunogen.com/news-releases/news-release-details/immunogen-provides-regulatory-update-mirvetuximab-soravtansine Conference Call to be Held at 8:00 a.m. ET Today WALTHAM, Mass. --(BUSINESS WIRE)--May 15, 2019-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the United States Food and Drug Administration ( FDA ) Wed, 15 May 2019 06:30:00 -0400 ImmunoGen, Inc. News Releases 18791 ImmunoGen Reports Recent Progress and First Quarter 2019 Financial Results http://investor.immunogen.com/news-releases/news-release-details/immunogen-reports-recent-progress-and-first-quarter-2019 Encouraging Efficacy Signal Observed in Pre-Specified Subset of Patients in Phase 3 FORWARD I Study; Company to Meet with Regulators this Quarter to Discuss Potential Path Forward for Mirvetuximab Soravtansine Monotherapy FORWARD II Trial with Mirvetuximab Combinations Continues to Enroll, with Fri, 03 May 2019 06:30:00 -0400 ImmunoGen, Inc. News Releases 18761 ImmunoGen Announces Conference Call to Discuss Its First Quarter 2019 Operating Results http://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-conference-call-discuss-its-first-quarter-1 WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 18, 2019-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. Thu, 18 Apr 2019 16:30:00 -0400 ImmunoGen, Inc. News Releases 18741 ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer http://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-top-line-results-phase-3-forward-i-study Trial Did Not Meet Primary Endpoint of Progression-Free Survival Efficacy Signal Seen in High Folate Receptor Alpha Patients; Additional Analyses to be Conducted Favorable Tolerability Profile Confirmed Combination Regimens to be Evaluated as an Independent Path Forward to Support Registration in Fri, 01 Mar 2019 06:30:00 -0500 ImmunoGen, Inc. News Releases 18696 ImmunoGen Announces Multiple Presentations at AACR Annual Meeting http://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-multiple-presentations-aacr-annual-meeting Continued Innovation in ADCs Highlighted in Eleven Posters First-in-Class ADAM9-targeting ADC, IMGC936, Developed in Collaboration with MacroGenics , Demonstrates Preclinical Activity in Models of Non-Small Cell Lung, Gastric, and Colorectal Cancers Novel DARPin ® Drug Conjugate Platform Evaluated Wed, 27 Feb 2019 16:31:00 -0500 ImmunoGen, Inc. News Releases 18686 ImmunoGen Reports Recent Progress and 2018 Operating Results http://investor.immunogen.com/news-releases/news-release-details/immunogen-reports-recent-progress-and-2018-operating-results Top-Line Data from Phase 3 FORWARD I Mirvetuximab Soravtansine Study on Track for First Half of 2019 Encouraging Clinical Data from Novel IGN Pipeline Highlighted in Two Oral Presentations at ASH 2018 Sale of Kadcyla ® Royalty Tail for $65 Million Further Strengthens Financial Position Conference Fri, 08 Feb 2019 06:30:00 -0500 ImmunoGen, Inc. News Releases 18616 ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results http://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-conference-call-discuss-its-2018-operating WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 24, 2019-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at  8:00 a.m. Thu, 24 Jan 2019 16:30:00 -0500 ImmunoGen, Inc. News Releases 18551 ImmunoGen Announces Sale of Residual Kadcyla Royalties http://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-sale-residual-kadcyla-royalties Company to Receive $65 Million Payment WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 8, 2019-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the sale of its residual rights to receive royalty payments on Tue, 08 Jan 2019 16:01:00 -0500 ImmunoGen, Inc. News Releases 18521 ImmunoGen Announces Webcast of Presentation and Q&A at the 37th Annual J.P. Morgan Healthcare Conference http://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-webcast-presentation-and-qa-37th-annual-jp WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 2, 2019-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, will present at the upcoming 37 th Annual J.P. Wed, 02 Jan 2019 08:30:00 -0500 ImmunoGen, Inc. News Releases 18471